Comparative Pharmacology
Head-to-head clinical analysis: TENORETIC 100 versus TENORETIC 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TENORETIC 100 versus TENORETIC 50.
TENORETIC 100 vs TENORETIC 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tenoretic 100 is a combination of atenolol (a cardioselective beta-1 adrenergic receptor antagonist) and chlorthalidone (a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule). Atenolol reduces heart rate, cardiac output, and blood pressure by blocking beta-1 receptors; chlorthalidone reduces plasma volume and peripheral resistance.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume.
One tablet orally once daily, each tablet containing atenolol 100 mg and chlorthalidone 25 mg. May be increased to 2 tablets once daily if needed.
1 tablet (atenolol 50 mg / chlorthalidone 25 mg) orally once daily, may increase to 2 tablets once daily if needed.
None Documented
None Documented
Atenolol: terminal half-life 6-7 h (up to 14 h in severe renal impairment); Chlorthalidone: 40-60 h (long-acting diuretic).
Atenolol: 6-7 hr (up to 20 hr in renal impairment); chlorthalidone: 40-60 hr (prolonged in renal impairment)
Tenoretic 100 (atenolol 100 mg + chlorthalidone 25 mg): Atenolol: ~85% renal unchanged, <10% fecal; Chlorthalidone: ~65% renal unchanged, remainder biliary/fecal.
Renal: atenolol 40-50% unchanged, chlorthalidone >95% unchanged; biliary/fecal minimal
Category C
Category C
Beta blocker/thiazide diuretic combination
Beta blocker/thiazide diuretic combination